Karen W Yee

Karen W Yee

UNVERIFIED PROFILE

Are you Karen W Yee?   Register this Author

Register author
Karen W Yee

Karen W Yee

Publications by authors named "Karen W Yee"

Are you Karen W Yee?   Register this Author

53Publications

1803Reads

39Profile Views

Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.

Expert Opin Investig Drugs 2019 Oct 19;28(10):835-849. Epub 2019 Sep 19.

Division of Medical Oncology and Hematology, University Health Network - Princess Margaret Cancer Centre , Toronto , Ontario , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1667331DOI Listing
October 2019

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.

Support Care Cancer 2019 Jun 19;27(6):2295-2300. Epub 2018 Oct 19.

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-018-4515-4DOI Listing
June 2019

Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.

Hematol Oncol 2017 Dec 6;35(4):810-813. Epub 2016 Sep 6.

Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2341DOI Listing
December 2017

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.

Clin Lymphoma Myeloma Leuk 2017 11 29;17(11):774-781. Epub 2017 Jun 29.

Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.06.031DOI Listing
November 2017

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.

Expert Opin Pharmacother 2017 Nov 20;18(16):1765-1780. Epub 2017 Oct 20.

a Division of Medical Oncology and Hematology , University Health Network - Princess Margaret Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1391216DOI Listing
November 2017

A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.

Invest New Drugs 2016 10 12;34(5):614-24. Epub 2016 Jul 12.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0375-2DOI Listing
October 2016

Tolerability of Vidaza (azacitidine) subcutaneous administration using a maximum volume of 3 ml per injection.

J Oncol Pharm Pract 2016 Aug 5;22(4):605-10. Epub 2015 Aug 5.

Department of Pharmacy, Princess Margaret Cancer Centre, UHN Toronto, ON

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155215598854DOI Listing
August 2016

Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.

Br J Haematol 2014 Jul 21;166(2):303-6. Epub 2014 Mar 21.

Division Medical Oncology & Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12844DOI Listing
July 2014

Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.

Leuk Res 2014 May 5;38(5):532-6. Epub 2013 Nov 5.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.10.025DOI Listing
May 2014

Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol.

Br J Haematol 2013 Nov 13;163(4):458-64. Epub 2013 Sep 13.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12561DOI Listing
November 2013

High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.

Leuk Res 2013 May 26;37(5):556-60. Epub 2013 Jan 26.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.01.001DOI Listing
May 2013

Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.

Cancer 2012 Dec 26;118(24):6110-7. Epub 2012 Jun 26.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.27683
Publisher Site
http://dx.doi.org/10.1002/cncr.27683DOI Listing
December 2012

Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen.

Leuk Res 2012 Dec 30;36(12):1517-20. Epub 2012 Aug 30.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.08.019DOI Listing
December 2012

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.

Br J Haematol 2012 Aug 1;158(4):506-14. Epub 2012 Jun 1.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2012.09182.xDOI Listing
August 2012

Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.

Am J Hematol 2012 Mar 27;87(3):323-6. Epub 2011 Dec 27.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22268DOI Listing
March 2012

Older patients with acute myeloid leukemia.

Expert Rev Hematol 2010 Dec;3(6):755-74

Division of Medical Oncology and Hematology, University Health Network-Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.10.68DOI Listing
December 2010

Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia.

Leuk Lymphoma 2010 Jan;51(1):61-5

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428190903388376DOI Listing
January 2010

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

Br J Haematol 2009 Jun 4;146(1):76-85. Epub 2009 May 4.

Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07712.xDOI Listing
June 2009

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

Clin Cancer Res 2006 Sep;12(17):5165-73

Authors' Affiliations: Departments of Leukemia and Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0764DOI Listing
September 2006

Chronic lymphocytic leukemia: diagnosis and treatment.

Mayo Clin Proc 2006 Aug;81(8):1105-29

Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4065/81.8.1105DOI Listing
August 2006

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.

Leuk Res 2006 Jul 14;30(7):813-22. Epub 2006 Feb 14.

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2005.12.013DOI Listing
July 2006

Emerging drugs for chronic lymphocytic leukaemia.

Expert Opin Emerg Drugs 2006 Mar;11(1):167-89

Department of Leukaemia, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.11.1.167DOI Listing
March 2006

Clinical experience with decitabine in North American patients with myelodysplastic syndrome.

Ann Hematol 2005 Dec;84 Suppl 1:18-24

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-005-0019-7DOI Listing
December 2005

Richter's syndrome: biology and therapy.

Cancer J 2005 May-Jun;11(3):161-74

Section of Developmental Therapeutics, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00130404-200505000-00001DOI Listing
October 2005

An update on the management of chronic lymphocytic leukaemia.

Expert Opin Pharmacother 2004 Jul;5(7):1535-54

University of Texas MD Anderson Cancer Center, Section of Developmental Therapeutics, Department of Leukaemia, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.5.7.1535DOI Listing
July 2004

NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases.

Biochem Biophys Res Commun 2003 Sep;308(4):784-92

Department of Medical Biophysics, University of Toronto, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ont., Canada M5G 2M9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(03)01475-xDOI Listing
September 2003

Advances in targeted therapy for chronic myeloid leukemia.

Expert Rev Anticancer Ther 2003 Jun;3(3):295-310

Department of Medical Oncology and Hematology, Princess Margaret Hospital, Ontario, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.3.3.295DOI Listing
June 2003

Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?

J Clin Oncol 2003 Apr;21(8):1618-23

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, 5-210, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.12.044DOI Listing
April 2003